Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.
Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.
复制标题
DOI：
10.1517/14740338.4.5.821
复制
发表时间：
2005-09-01
影响因子：
3.1
通讯作者：
Bonora, Stefano
中科院分区：
文献类型：
--
作者：
Di Perri, Giovanni;Aguilar Marucco, Diego;Bonora, Stefano
在世界范围内，结核病（TB）是HIV感染者中最重要的传染病之一。虽然对这两种情况都有有效的治疗方法，但在同时治疗艾滋病毒和结核病合并感染方面存在重大问题。在这篇文章中，抗艾滋病毒和抗结核化合物之间的药物相互作用的知识进行了分析，特别是在药理学相互作用继发于干扰细胞色素P450酶。在同一背景下，事实和可能的解释遇到的问题，在结核病和艾滋病毒的同时治疗的耐受性和安全性进行审查。目前的准则，以及其他可能的战略，在这一特定的合并症的设置进行了讨论。
Worldwide, tuberculosis (TB) is one of the most important infectious diseases in subjects with HIV infection. Although effective therapy is available for both conditions, there are major problems in the concurrent treatment of HIV and TB co-infection. In this article the knowledge available on drug-drug interactions between anti-HIV and anti-TB compounds is analysed, particularly with regard to pharmacological interactions secondary to interference with cytochrome P450 enzymes. Within the same setting, facts and possible interpretations of the problems encountered in terms of tolerance and safety of the concurrent treatment of TB and HIV are also reviewed. Current guidelines, as well as additional possible strategies to be adopted in this particular co-morbidity setting are discussed.